Endo International plc (ENDPQ)

0.0006 0.0000 (0.00%) At close: 01:55PM EDT

Endo International plc

Minerva House
First Floor Simmonscourt Road Ballsbridge
Dublin 4
Ireland
353 1 268 2000
https://www.endo.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 2,931

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Blaise A. Coleman	President, CEO & Director	12.85M	N/A	1974
Mr. Matthew Joseph Maletta	Executive VP, Chief Legal Officer & Company Secretary	4.25M	N/A	1972
Dr. James Patrick Tursi M.D.	Executive Vice President of Global Research & Development	5.46M	N/A	1965
Mr. Mark T. Bradley	Executive VP & CFO	6.27M	N/A	1969
Frank B. Raciti	VP, Controller & Chief Accounting Officer	N/A	N/A	N/A
Ms. Cheryl Stouch	Senior VP of Information Technology & Chief Information Officer	N/A	N/A	N/A
Ms. Laure E. Park	Senior Vice President of Investor Relations & Corporate Affairs	N/A	N/A	N/A
Ms. Susan Williamson	Senior VP & Chief Compliance Officer	N/A	N/A	N/A
Ms. Tracy Basso	Chief Human Resources Officer	N/A	N/A	N/A
Mr. Patrick A. Barry	Executive VP & President of Global Commercial Operations	6.15M	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's contracture and Peyronie's disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia. It also provides ADRENALIN, a non-selective adrenergic agonist to treat anaphylaxis; VASOSTRICT, a vasopressin IV solution; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. In addition, the company offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. Further, it provides specialty pharmaceutical products and over-the-counter products. The company sells its products to specialty physicians, wholesale distributors, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Corporate governance

Endo International plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.